Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. is set to hold its IPO on the Sci-Tech Innovation Board on October 21, marking a significant milestone in the company's development and contributing to the domestic high-end medical equipment localization process [1] Company Overview - Jianxin Superconducting has been deeply engaged in the MRI core component sector for many years, focusing on the R&D, production, and sales of superconducting magnets, permanent magnets, and gradient coils, which account for approximately 50% of the cost of MRI equipment [1][2] - The company has established a leading core technology system in the superconducting field, offering a diverse product matrix including 1.5T zero-evaporation superconducting magnets and 3.0T zero-evaporation superconducting magnets, making it the world's top independent supplier of superconducting magnets in the MRI industry [1][2] Market Position and Achievements - Since 2015, Jianxin Superconducting has broken the long-standing monopoly of European, American, and Japanese manufacturers in the zero-evaporation superconducting magnet sector, significantly enhancing the domestic MRI equipment localization rate [2] - The company has received national recognition for its technological contributions, with its 3.0T zero-evaporation superconducting magnet recognized as a "provincial first set of equipment" in 2020 [2] - Jianxin Superconducting is the largest supplier of MRI permanent magnets globally, with a focus on high-quality products that support the widespread adoption of MRI equipment in grassroots medical systems [3] Financial Performance - The company's revenue from 2022 to the first half of 2025 shows a steady increase, with figures of 358.93 million, 450.64 million, 425.50 million, and 252.10 million yuan, respectively, while net profits were 34.63 million, 48.73 million, 55.78 million, and 31.92 million yuan [3] - In 2024, the company is expected to achieve bulk supply to GE Healthcare, breaking into the supply chain of leading integrated equipment manufacturers, which opens up significant growth opportunities [3] IPO and Future Plans - Jianxin Superconducting plans to issue up to 41.92 million shares in its IPO, with funds primarily allocated to projects for annual production of 600 sets of liquid-helium-free superconducting magnets and high-field medical superconducting magnets [4] - The fundraising projects are closely aligned with the company's main business, aiming to expand production capacity, enhance product layout, and strengthen R&D capabilities, while also promoting the industrial application of superconducting technology in sectors like power and transportation [4] Industry Outlook - The MRI core component market is poised for significant growth due to increasing global healthcare demands, accelerated adoption of MRI equipment in emerging markets, and ongoing domestic medical equipment localization policies [4] - Jianxin Superconducting, with its technological leadership and market recognition, is well-positioned to expand its market share and contribute to enhancing the self-sufficiency of high-end medical equipment in China [4]